Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massar Omar

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
JAMA Cardiology|July 24, 2024
Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical TrialYogesh N V Reddy, Rickey E Carter, Hidemi Sorimachi, et al.
Circulation|August 3, 2023
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA TrialBarry A Borlaug, Yogesh N V Reddy, Amanda Braun, et al.
European Journal of Heart Failure|March 30, 2023
Ventricular stiffening and chamber contracture in heart failure with higher ejection fractionDejana Popovic, Alessio Alogna, Massar Omar, et al.
Circulation. Heart Failure|August 16, 2022
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure TrialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
Circulation|August 8, 2022
Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide LevelsHidemi Sorimachi, Frederik H Verbrugge, Kazunori Omote, et al.
European Heart Journal|July 7, 2022
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implicationsKazunori Omote, Hidemi Sorimachi, Masaru Obokata, et al.
Circulation|June 1, 2021
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
JACC. Heart Failure|September 12, 2021
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart FailureMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
European Journal of Heart Failure|June 15, 2023
Hypoxaemia in patients with heart failure and preserved ejection fractionMassar Omar, Kazunori Omote, Hidemi Sorimachi, et al.
European Journal of Heart Failure|December 7, 2023
Biatrial myopathy in heart failure with preserved ejection fractionKazunori Omote, Hidemi Sorimachi, Masaru Obokata, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
JAMA Cardiology|July 24, 2024
Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical TrialYogesh N V Reddy, Rickey E Carter, Hidemi Sorimachi, et al.
Circulation|August 3, 2023
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA TrialBarry A Borlaug, Yogesh N V Reddy, Amanda Braun, et al.
European Journal of Heart Failure|March 30, 2023
Ventricular stiffening and chamber contracture in heart failure with higher ejection fractionDejana Popovic, Alessio Alogna, Massar Omar, et al.
Circulation. Heart Failure|August 16, 2022
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure TrialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
Circulation|August 8, 2022
Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide LevelsHidemi Sorimachi, Frederik H Verbrugge, Kazunori Omote, et al.
European Heart Journal|July 7, 2022
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implicationsKazunori Omote, Hidemi Sorimachi, Masaru Obokata, et al.
Circulation|June 1, 2021
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
JACC. Heart Failure|September 12, 2021
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart FailureMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
European Journal of Heart Failure|June 15, 2023
Hypoxaemia in patients with heart failure and preserved ejection fractionMassar Omar, Kazunori Omote, Hidemi Sorimachi, et al.
European Journal of Heart Failure|December 7, 2023
Biatrial myopathy in heart failure with preserved ejection fractionKazunori Omote, Hidemi Sorimachi, Masaru Obokata, et al.
Pageof 5